Harpoon Therapeutics — Investor Presentation (January 2022)
40 slides from Harpoon Therapeutics's investor presentation, Jan 11, 2022
Slide 1: Spearheading Immunotherapies Investor Presentation January 2022
Spearheading Immunotherapies Investor Presentation January 2022 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate” and similar expressions (as well as other words or expre
Slide 3: Clinical-Stage Immuno-Oncology Company Advancing a Novel Portfolio of T Cell Engagers
Clinical-Stage Immuno-Oncology Company Advancing a Novel Portfolio of T Cell Engagers Redirecting T Cells to Become Cancer Killers Strong Capabilities Broad Pipeline in Immuno-Oncology Novel T Cell Engaging Platforms Deep expertise in oncology, T cell engagement, and protein engineering Well-positio
Slide 4: Broad Pipeline of Immuno-Oncology Programs
TriTAC Oncology ProTriTAC Oncology TriTAC-XR Oncology/ Non-Oncology Program Stage of Development Preclinical Phase 1 Phase 2 HPN328 (DLL3) Small Cell Lung Cancer & Other Tumors HPN2171 (BCMA) Multiple Myeloma HPN536 (MSLN) Ovarian, Pancreatic & Other Solid Tumors HPN424 (PSMA) Prostate Cancer HPN601
Slide 5: HPN328 TriTAC Targeting DLL3
HPN328 TriTAC Targeting DLL3
Slide 6: Small Cell Lung Cancer Comprises ~13% of All Lung Cancers
Small Cell Lung Cancer (SCLC) Comprises ~13% of All Lung Cancers; Aggressive Disease and Outsized Unmet Need Chemo- and/or radiation therapy has been the SoC as frontline treatment; Limited utilization due to suboptimal efficacy and significant toxicity Most patients relapse Recently-approved immuno
Slide 7: HPN328 Phase 1/2 Study
HPN328 Phase 1/2 Study An Open-Label, Multi-Center, Dose Escalation / Expansion, Safety & PK Study Target population Small cell lung cancer relapsed after platinum chemotherapy Other malignancies with high grade neuroendocrine features R/R to standard of care (SOC) or no SOC available Trial objectiv
Slide 8: HPN328: Dose Cohorts
HPN328: Dose Cohorts 480-Fold Escalation Accomplished Data as of December 2, 2021 Dose Level (µg/week) n 15 1 45 1 135 1 405 3 1215 4 3600 1 3600 (priming)→7200 (target) 4 Total 15
Slide 9: HPN328 Baseline Demographics
HPN328 Baseline Demographics 93% of Patients Had Prior Anti-PD-1/PD-L1 Treatment *Other NET: Colorectal, Retroperitoneal, Pancreatic, Thymic Data as of December 2, 2021 Baseline Characteristics Total N = 15 Age (yr), Median (range) 61 (43 – 73) ECOG performance status 0-1, n (%) 15 (100) Brain / Liv
Slide 10: HPN328: Safety and Tolerability
No dose-limiting toxicities observed Maximum tolerated dose not reached CRS events: 5 of 15 patients experienced CRS (G1-2) All CRS events were managed with standard medications and resolved within hours When CRS occurred, it typically followed the first dose and did not recur on subsequent dosing T
Slide 11: HPN328 Time on Treatment
HPN328 Time on Treatment 3600 3600 3600 uPR -38% TL chg (week 9) Confirmed PR -53% TL chg (week 9) -21% TL chg (Week 9) -27% TL chg (Week 9) Dose Increase SCLC Prior PD1/L1 inhibitor Ongoing NEPC NET Other * % Target Lesion Reduction from Baseline -X% Objective Response (RECIST v1.1) CR, PR Dose (μg
Slide 12: HPN328 SCLC Patients Anti-tumor Activity at Higher Doses
HPN328 SCLC patients Anti-tumor Activity at Higher Doses, Including Confirmed PR At doses of ≥1215μg/wk: 3/4 SCLC patients had target lesion (TL) reductions Dose (μg/week) * * * * * On study treatment aRECIST 1.1 Criteria: -Partial Response: 30% or greater TL reduction -Progressive Disease: 20% incr
Slide 13: HPN328 Patient Case One: SCLC
61-year-old female Diagnosed in January 2021 with extensive SCLC Location of metastases: TLs: lung, liver x2, lymph nodes x2 Non-TLs: lung x2, liver Prior systemic treatment: carboplatin etoposide+atezolizumab Time on most recent prior systemic treatment: 20.1 weeks Upon study entry, stable disease
Slide 14: HPN328 Patient Case One: SCLC Imaging
Pre-Treatment Week 6 Post-Treatment Week 10 Post-Treatment 38% reduction at wk 6 53% reduction at wk 10 HPN328 Patient Case One: SCLC 53% Reduction in Sum of Target Lesion Diameters at Week 10 Confirmed PR Lymph Node Lung Liver Data as of December 2, 2021
Slide 15: HPN328 Patient Case Two: SCLC
67-year-old male Diagnosed in April 2020 with extensive SCLC Location of metastases TLs: liver x2, lymph nodes x2 Non-TLs: liver, lymph nodes x2, spleen, bone, brain Prior systemic treatment Carboplatin + etoposide + toripalimab (anti-PD1) (4 cycles – clinical trial) Cisplatin + etoposide (2 cycles)
Slide 16: Clinical Summary HPN328
Clinical Summary HPN328 Manageable Safety Profile and Activity at Doses > 1215 µg/week HPN328 is well-tolerated No Grade 3 CRS to date Grade 1-2 CRS in 33% of patients No DLTs MTD not yet identified HPN328 activity signal at doses ≥1215 μg/week: Small Cell Lung Cancer 3 out of 4 patients with target
Slide 17: HPN217 TriTAC Targeting BCMA
HPN217 TriTAC Targeting BCMA
Slide 18: Multiple Myeloma is a Progressive Disease
Multiple Myeloma is a progressive disease; depth and duration of response are weak in penta-refractory patients 74% CR /VGPR 58% CR /VGPR 43% CR /VGPR <10% CR /VGPR 1Bird SA, Boyd K. Palliat Care Soc Pract. 2019;13:1-13 3Gandhi, et al., Leukemia. 2019 September ; 33(9): 2266–2275. doi:10.1038/s41375
Slide 19: HPN217-3001 Phase 1/2 Trial Design
HPN217-3001 Phase 1/2 Trial Design Relapsed/Refractory Multiple Myeloma *International Myeloma Working Group Uniform Response Criteria For Multiple Myeloma and Minimal Residual Disease Assessment in Multiple Myeloma Target Population is R/R MM Disease progressing at time of study entry At least 3 pr
Slide 20: HPN217 Patient Baseline Characteristics
HPN217 Patient Baseline Characteristics: Heavily Pretreated R/R Multiple Myeloma Population Baseline Characteristics Total N = 37 Age (yr), Median (range) 71 (38 – 78) Duration of Disease (yr), Median (range) 8 (1 – 20) Prior Transplantation, N (%) 28 (76%) Prior Systemic Therapies, Median (range) 7
Slide 21: Reported Adverse Events: HPN217 Has Manageable Safety Profile
Reported Adverse Events HPN217 Has Manageable Safety Profile Event Grade 1 or Grade 2 ≥ Grade 3 All Grades (N=37) Hematological Adverse Events* Anemia 3 (8%) 14 (38%) 17 (46%) Non-Hematological Adverse Events* Fatigue 11 (30%) 1 (3%) 12 (32%) Aspartate Aminotransferase Increase 2 (5%) 5 (14%) 7 (19%
Slide 22: HPN217 Adverse Events: Focus on CRS
HPN217 Adverse Events: Focus on CRS No Grade 3 CRS Events Reported to Date Event 5/15/30/90/270 µg/wk (N=7) 810 µg/wk (N=4) 1620 µg/wk (N=6) 2150 µg/wk (N=11) 2860 µg/wk (N=6) 1620→3240 µg/wk (N=3) Total (N=37) CRS (Grade 1 or Grade 2) 0 (0%) 0 (0%) 1 (17%) 6 (55%) 2 (33%) 0 (0%) 9 (24%) CRS Grade 1
Slide 23: HPN217 on Treatment Activity Emerging in Higher Dose Cohorts
HPN217 on Treatment Activity Emerging in Higher Dose Cohorts Time on Treatment for All Patients Treated Data as of November 10, 2021 IMWG assessments obtained every six weeks 5 15 30 90 270 810 1620 2150 2860 3240
Slide 24: HPN217 IMWG Responses
HPN217 IMWG Responses Threshold Effect: Responses obtained at higher doses Data as of November 10, 2021 ORR* (PR and better) DCR** (SD and better) Median Time on Treatment (wks) 5 – 810 µg/week 0/11 (0%) 4/11 (36%) 7 (3-25) 1620 µg/week 0/6 (0%) 3/6 (50%) 8 (2-17) 2150 µg/week 5/8 (63%) 7/8 (88%) 12
Slide 25: Clinical Summary HPN217
Clinical Summary HPN217 Manageable Safety Profile and Active at Doses > 2150 µg/week HPN217 is generally well tolerated Transient low-grade CRS in 24% of patients, no Grade 3 reported to date MTD has not been reached one DLT of Grade 4 AST, resolved HPN217 is active 7 of 8 disease evaluable patients
Slide 26: HPN536 TriTAC Targeting Mesothelin
HPN536 TriTAC Targeting Mesothelin
Slide 27: HPN536 Phase 1/2a Trial Design and Status
HPN536 Phase 1/2a Trial Design and Status Mesothelin-Targeting TriTAC Enrolling Late-stage Ovarian, Pancreatic and Mesothelioma Cancer Patients HPN536 escalation study ongoing in multiple indications 83 patients enrolled Target doses up to 3600 ng/kg achieved Now enrolling cohort to evaluate target
Slide 28: HPN424 TriTAC Targeting PSMA
HPN424 TriTAC Targeting PSMA
Slide 29: HPN424 Trial Design and Status
HPN424 Trial Design and Status Target Population Disease progression on the prior systemic regimen At least two prior systemic therapies approved for mCRPC Prior chemotherapy allowed, but not required Trial Design Objectives include characterization of safety, PK, pharmacodynamics and identification
Slide 30: HPN424-1001 Phase I Dose Escalation Status Update and Next Steps
HPN424-1001 Phase I Dose Escalation Status Update and Next Steps 102 patients enrolled across all cohorts Escalation ongoing 450 ng/kg Step Dose Fully Enrolled MTD not identified Safety profile manageable with pre-treatment and step dosing up to 450 ng/kg HPN424 activity seen in patients with reduct
Slide 31: Clinical Summary
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase Learnings from earlier programs have enabled rapid dose escalation and effective CRS management Encouraging profile of tolerability and activity seen at higher doses These data va
Slide 32: Harpoon's T Cell Engager Platforms
Harpoon’s T Cell Engager Platforms
Slide 33: T Cell Engager Platforms Are Optimized to Address Target-Specific Safety Concerns
T cell Engager Platforms Are Optimized to Address Target-Specific Safety Concerns TriTAC ProTriTAC TriTAC-XR Prodrug Active αALB αTarget αCD3 Finalizing platform validation Maximize systemic exposure while minimizing CRS Heme malignancies and solid tumors with potential expansion to non-oncology Fou
Slide 34: Platforms Designed To Address T Cell Engager Associated Toxicities
Platforms Designed To Address T Cell Engager Associated Toxicities Prodrug administered systemically Active drug formed through local activation at tumor site Active drug has short half-life Prodrug administered systemically Active drug formed systemically, but in a slow, controlled fashion Active d
Slide 35: Harpoon's First ProTriTAC HPN601 Designed to Target EpCAM
Harpoon’s First ProTriTAC HPN601 Is Designed to Target EpCAM, Potentially Addressing Large Unmet Medical Need Tumor EpCAM Expression1 (% moderate/high expression by IHC) HPN601 Population2 (estimated annual incidence in USA) Prostate 89 171,000 NSCLC 74 147,000 Breast 46 128,000 Colon 94 99,000 Endo
Slide 36: Committed To Developing Next-Generation T Cell Engagers
Harpoon Is Committed To Developing Next-Generation T Cell Engagers and Expanding Their Therapeutic Applications Solid tumor Heme Utility TriTAC ✓ ✓ Most robust platform minimizing off-target toxicities ProTriTAC ✓ Spatial control of activity to address on-target tissue damage TriTAC-XR ✓ ✓ Temporal
Slide 37: Financial Snapshot
Notes Cash, Cash Equivalents and Marketable Securities $154.2M Expected to fund operations into 1H 2023 No debt As of September 30, 2021 Shares Outstanding 32.7M As of October 31, 2021 Market Capitalization $247M As of December 31, 2021 Non-affiliated Institutional Ownership 51.4% As of January 6, 2
Slide 38: 2022 Harpoon Milestones
Program Milestone Anticipated Timing HPN217 Select the recommended Phase 2 dose (RP2D) and initiate expansion cohort(s) 1H 2022 Platform technology and selected clinical data R&D Day 1H 2022 HPN424 Complete dose escalation 2H 2022 Platform technologies Move new clinical candidate into IND-enabling s
Slide 39: Summary & Conclusions
Summary & Conclusions HARP: a clinical-Stage immuno-oncology company developing three novel classes of T cell engagers TriTAC ProTriTAC TriTAC XR Four TriTACs in clinical development in US, UK and EU All programs in dose-escalation across multiple indications All levels of target expression eligible
Slide 40: Spearheading Immunotherapies
Spearheading Immunotherapies
Harpoon Therapeutics — Investor Presentation (January 2022) on 6ix